• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Share
News

ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife

January 31, 2022
-
Posted by Jessica Robinson

ProAxsis Limited, the Belfast-based diagnostics company, today announces an expansion of its activities in Asia, via a partnership with Kyberlife, a Singapore-based company offering a novel e-commerce platform.

The partnership will initially enable the company’s existing product portfolio, including laboratory-based assays for the active forms of Neutrophil Elastase and Proteinase 3, and a point-of-care test for Neutrophil Elastase (NEATstik®) to be listed on the site.  The company will also have the option to add in new products as they become commercially available in Europe.

Dr David Ribeiro, Chief Executive Officer at ProAxsis, said: “Kyberlife offers the first open marketplace in Asia with an easy-to-use platform that hosts a multitude of global healthcare vendors, including companies such as Roche and Merck.  We’re delighted to be able to make it easier for laboratories across Asia, a key market for our respiratory diagnostics, to be able to make purchases from our portfolio of products.”

Further information on ProAxsis’ range of products can be found at www.proaxsis.com

About ProAxsis

ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

The company has significantly expanded its product portfolio, via the recent in-licensing of a novel bone health assay from the University of Geneva, and a COVID-19 serology assay from AstraZeneca.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.

January 31, 2022

Related News

Other posts that you should not miss.
News

ProAxsis builds market presence

June 20, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland support. Speaking about the plans, Dr David …

Read More
June 20, 2016
Posted by Webmaster
News

ProAxsis enhances portfolio with new CE Marked Immunoassay

August 2, 2018
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers …

Read More
August 2, 2018
Posted by David Ribeiro
News, ProteaseTag®

ProAxsis abstracts at 2017 American Thoracic Society Conference

May 5, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes …

Read More
May 5, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
NEXT POST →
ProAxsis expands inflammatory biomarker research via new partnership with Queen’s University Belfast
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • July 26, 2022
    ProAxsis announces additional key appointments
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife - ProAxsis